These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21734418)

  • 41. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
    Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
    Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
    Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
    J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
    Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
    Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
    Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Capecitabine plus docetaxel combination therapy.
    Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
    Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
    Yamamoto D; Sato N; Rai Y; Yamamoto Y; Saito M; Iwata H; Masuda N; Oura S; Watanabe J; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Feb; 161(3):473-482. PubMed ID: 28005247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
    Yu J; DI Lj; Song Gh; Che L; Jiang Hf; Zhu Yl; Liang X; Jia J; Zhang J; Yang Hb; Wang Xl; Zhou Xn; Ren J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):151-6. PubMed ID: 21321641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.
    Hainsworth JD; Yardley DA; Spigel DR; Meluch AA; Rinaldi D; Schnell FM; Greco FA
    Cancer Invest; 2006; 24(5):469-73. PubMed ID: 16939953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.
    Wardley A
    Oncologist; 2006; 11 Suppl 1():20-6. PubMed ID: 16971736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
    Seidman AD; Brufsky A; Ansari RH; Hart LL; Stein RS; Schwartzberg LS; Stewart JF; Russell CA; Chen SC; Fein LE; De La Cruz Vargas JA; Kim SB; Cavalheiro J; Zhao L; Gill JF; Obasaju CK; Orlando M; Tai DF
    Ann Oncol; 2011 May; 22(5):1094-1101. PubMed ID: 21084429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
    Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
    Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
    Buzdar AU; Xu B; Digumarti R; Goedhals L; Hu X; Semiglazov V; Cheporov S; Gotovkin E; Hoersch S; Rittweger K; Miles DW; O'Shaughnessy J; Tjulandin S;
    Ann Oncol; 2012 Mar; 23(3):589-597. PubMed ID: 21633047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
    Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
    Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
    Glück S; Russell C; O'Shaughnessy J; McKenna EF; Hu S; Odom D; Blum JL
    Breast; 2013 Dec; 22(6):1087-93. PubMed ID: 24095220
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
    Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
    Steger GG; Greil R; Lang A; Rudas M; Fitzal F; Mlineritsch B; Hartmann BL; Bartsch R; Melbinger E; Hubalek M; Stoeger H; Dubsky P; Ressler S; Petzer AL; Singer CF; Muss C; Jakesz R; Gampenrieder SP; Zielinski CC; Fesl C; Gnant M;
    Ann Oncol; 2014 Feb; 25(2):366-71. PubMed ID: 24347519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.